Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2903 - Platinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects – a multicentre retrospective analysis


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Cytotoxic Therapy

Tumour Site

Prostate Cancer


Silke Gillessen


Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284


S. Gillessen1, S. Schmid2, H. Beltran3, D.V.P. Almeida4, N. Mehra5, P. Lavaud6, R. Morales Barrera7, D. Pignataro8, E. Castro Marcos9, V. Conteduca3, E. Efstathiou10, H.M.L. Le11, C.V. Pezaro12, H. Suzuki13, A. Zivi14, D. Klingbiel15, A.G. Omlin16

Author affiliations

  • 1 Department Of Oncology/hematology  , Kantonsspital St. Gallen, 9007 - St. Gallen/CH
  • 2 Oncology And Haematology, Kantonsspital St. Gallen, 9007 - St. Gallen/CH
  • 3 Division Of Hematology And Medical Oncology, Weill Cornell Medical College, 10065 - New York/US
  • 4 Oncology, Hospital São Jose - Beneficencia Portuguesa de São Paulo, 01321-001 - Sao Paulo/BR
  • 5 Oncology, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL
  • 6 Department Of Medical Oncology, IGR - Insitut Gustave Roussy, 94800 - Villejuif/FR
  • 7 Department Of Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 8 Medical Oncology, Azienda Ospedaliera Universitaria San Luigi Gonzaga, 10043 - Orbassano/IT
  • 9 Prostate Cancer Unit, CNIO- Spanish National Cancer Center, 28029 - Madrid/ES
  • 10 Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030-3721 - Houston/US
  • 11 Medical Oncology, Guy's and St.Thomas Hospital, SE1 9RT - London/AE
  • 12 Oncology, Eastern Health, 3128 - Box Hill/AU
  • 13 Urology, Toho University Sakura Medical Center, 143-8540 - Tokio/JP
  • 14 Oncology, Ospedale dell'Angelo, Mestre, Venice/IT
  • 15 Swiss Group For Clinical Cancer Research Coordinating Center, SAKK, Bern/CH
  • 16 Medical Onocolgy And Haematology, Kantonsspital St. Gallen, 9007 - St. Gallen/CH


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2903


Platinum compounds have been tested in a larger number of mostly small to medium sized clinical trials in molecularly unselected prostate cancer patients (pts). Advances in castration-resistant prostate cancer (CRPC) molecular profiling have shown that a significant proportion of pts harbor DNA repair defects, which may serve as predictive markers for sensitivity to platinum agents. Our aim was to evaluate the antitumour activity of platinum agents in a contemporaneous mCRPC cohort with or without DNA repair defects.


International, multicenter retrospective database project in 14 centers worldwide. Pts with mCRPC treated with a platinum agent were included. Pts with primary pure small cell carcinoma and/or insufficient outcome data were excluded. For antitumour activity PSA levels at baseline, after 4-, 8- and 12-weeks of therapy (tx) were analyzed as well as soft tissue response and duration of platinum-based chemotherapy. Overall survival (OS) was analyzed by Kaplan Meier method.


A total of 167 pts have been included in this analysis, 33 (20%) received platinum monotherapy, 134 (80%) a platinum combination therapy. Carboplatin was used in 140 (84%), cisplatin in 26 (16%) of pts. Combination tx with etoposise was used in 45 (27%), paclitaxel in 35 (21%) and docetaxel in 28 (17%) of pts. At start of platinum tx median age was 68 years, median PSA 78 ug/l, median ALP 185 U/l, median hemoglobin 103 g/l. The metastatic sites at start of platinum therapy were: bone 84%, lymph node 59% and visceral 60%. Outcome data by DNA repair defect status are summarized in the table.Table: 814P

Outcome of platinum based txDNA repair defects: assessed, present N = 40DNA repair defects: assessed, not present N = 42DNA repair defects not assessed N = 85
N (%)N (%)N (%)
PSA decline ≥50%13/32 (41)8/23 (35)24/73 (33)
Soft tissue response (PR/CR)9/32 (28)7/29 (24)16/48 (33)
median time on platinum tx: months (m), interquartile range (IQR)2.5m (IQR 1.8-5.9)2.8m (IQR 1.4 – 4.6)3.5m (IQR 1.4 – 4.6)
OS from start of platinum therapy (m, IQR)9.1m (IQR 4.8 – NR)11m (IQR 6.7-22)12m (IQR 7-29)


In this retrospective analysis of a contemporary cohort of men with mCRPC and poor prognostic characteristics platinum-based treatment seems to have significant anti-tumor activity irrespective of DNA repair status. Comparison of subgroups is limited by small sample size. Updated analyses will be presented.

Clinical trial identification

Legal entity responsible for the study

Ethical Committee St. Gallen.


Has not received any funding.

Editorial Acknowledgement


S. Gillessen: Advisory boards (compensated): IDMC, AAA International, Active Biotech AB IDMC, Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis, Curevac, Dendreon Corporation, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxiVAX SA, Millennium Pharmaceuticals, Orion, Roche, Sanofi Aventis Group; Advisory boards (uncompensated): Astellas Pharma, Bayer, ESSA Pharmaceuticals Corp., Nectar, ProteoMediX, Sanofi; Speakers Bureau (compensated): Janssen, Novartis; Speakers bureau (uncompensated): Astellas Pharma, Janssen, Sanofi Aventis Group; Patent pending patent application for a method for biomarker WO 2009138392 A. H. Suzuki: Steering Committee: ACIS (ARN-509); Lead Principle Investigator: ARASENS (ODM-201); Advisory board: AstraZeneca, Bayer, Janssen, Nihon Medi-Physics, Kissei; Research funding: Takeda, Bayer, Astellas, Daiichi-Sankyo, Pfizer, Nihon Kayaku Ono; Honoraria: Astellas, AstraZeneca, Daiichi Sankyo, Janssen, Pfizer, Novartis, Sanofi, Takeda. A.G. Omlin: Advisory role (compensated, institutional): AstraZeneca, Astellas, Bayer, Janssen, Molecular Partners, MSD, Pfizer, Roche, Sanofi Aventis; Research support (institutional): TEVA, Janssen; Travel support: Astellas, Bayer, Janssen, Sanofi, Aventis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.